EUVIMEDEUVIMED entdecken
Crossref

B7–H4 ImmunoPET Imaging Tracks Tumor-Associated Macrophage Changes in Prostate Cancer

Manoj Kumar iD, Shashi B Singh, Iryna Vasyliv, Frezghi Habte, Mausam Kalita iD, Israt S Alam, Abhishek Koladiya, Sheng Yao Dai iD, Michelle James, Jianghong Rao iD, Nicolas Beziere iD, Heike E Daldrup-Link

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.5c00637 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Manoj Kumar und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Molecular Imaging Program at Stanford, Stanford University School of Medicine, Stanford, California 94305, United States. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Tumor-Associated Macrophages, V-Set Domain-Containing T-Cell Activation Inhibitor 1. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Werner Siemens-Stiftung, School of Medicine, Stanford University, Eberhard Karls Universit?t T?bingen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

B7-H4 is an inhibitory immune checkpoint molecule that is upregulated in various cancers and correlates with advanced tumor stages and poor clinical outcomes. This study aimed to develop an immunoPET radiotracer for noninvasive assessment of B7-H4 expression in tumors and tumor-associated macrophages (TAM) and to evaluate the radiotracer potential to monitor therapeutic responses. We generated a B7-H4-targeted immunoPET imaging tracer by radiolabeling the anti-B7-H4 monoclonal antibody (2H9) with [89Zr], yielding [89Zr]Zr-DFO-2H9, and assessed its biodistribution in prostate cancer xenografts to quantitatively measure B7-H4 expression in vivo. In vitro binding studies confirmed the retained immunoreactivity and specificity for B7-H4. Radiochemical purity was verified using size exclusion chromatography. In vivo evaluation of [89Zr]Zr-DFO-2H9 was first performed in immunodeficient nude mice bearing subcutaneous DU145 human prostate tumors, with longitudinal PET imaging conducted over 7 days postinjection, followed by terminal biodistribution analysis. [89Zr]Zr-DFO-2H9 demonstrated a good tumor-binding profile and specificity in DU145 tumor xenografts. To distinguish PET signals from tumor cells versus macrophages, immunocompetent C57BL/6 mice bearing syngeneic TRAMP-C2 prostate tumors were divided into three cohorts and treated with PBS (control), cold anti-B7-H4 mAb (for B7-H4 blockade), or clodronate liposome (for macrophage depletion). In TRAMP-C2 tumors, the PET signal was significantly reduced in both the B7-H4 blocked and macrophage-depleted group compared to controls. Immunohistochemistry revealed that B7-H4 expression differences among TRAMP-C2 treatment groups were not as clearly distinguishable as those observed in vivo via PET imaging. Multiplexed immunofluorescence staining of macrophage markers indicated that infiltrating TAMs were the major contributors to B7-H4-specific PET signals within the tumor stroma. Collectively, these results show that [89Zr]Zr-DFO-2H9 binds B7-H4 with high affinity and specificity and reflects changes in TAM levels in vivo. The new radiotracer shows promise for detecting B7-H4 positive tumors and TAM levels, profiling the immune microenvironment, and monitoring macrophage-targeted immunotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsTumor-Associated MacrophagesV-Set Domain-Containing T-Cell Activation Inhibitor 1AnimalsMaleHumansMiceZirconiumCell Line, TumorMice, NudeAntibodies, MonoclonalTissue DistributionRadioisotopesPositron-Emission TomographyXenograft Model Antitumor AssaysRadiopharmaceuticals

Stichwörter der Autor:innen

B7–H4 immunoPETT-cell suppressorimmune checkpointprostate cancertumor-associated macrophages (TAMs)

Substanzen

ZirconiumV-Set Domain-Containing T-Cell Activation Inhibitor 1Antibodies, MonoclonalRadioisotopesVTCN1 protein, humanZirconium-89Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Radiology, Molecular Imaging Program at Stanford, Stanford University School of Medicine, Stanford, California 94305, United States.
  • Stanford Cancer Institute, Stanford University, Stanford, California 94305, United States.
  • Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University, Stanford, California 94305, United States.
  • Department of Pediatrics, Division of Hematology, Oncology, and Stem Cell Transplant and Regenerative Medicine, Stanford University, Stanford, California 94305, United States.
  • Department of Neurology and Neurological Sciences, Stanford University, Stanford, California 94305, United States.
  • Department of Chemistry, Stanford University, Stanford, California 94305, United States.

ORCID-Profile: Manoj Kumar, Mausam Kalita, Sheng Yao Dai, Jianghong Rao, Nicolas Beziere

Förderung

  • Werner Siemens-Stiftung
  • School of Medicine, Stanford University
  • Eberhard Karls Universit?t T?bingen

Zitieren

APA

Kumar, M., Singh, S. B., Vasyliv, I., Habte, F., Kalita, M., Alam, I. S., Koladiya, A., Dai, S. Y., James, M., Rao, J., Beziere, N., & Daldrup-Link, H. E. (2025). B7–H4 ImmunoPET Imaging Tracks Tumor-Associated Macrophage Changes in Prostate Cancer. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00637

Vancouver

Kumar M, Singh SB, Vasyliv I, Habte F, Kalita M, Alam IS, et al. B7–H4 ImmunoPET Imaging Tracks Tumor-Associated Macrophage Changes in Prostate Cancer. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00637

BibTeX
@article{Kumar2025,
  author = {Kumar, Manoj and Singh, Shashi B and Vasyliv, Iryna and Habte, Frezghi and Kalita, Mausam and Alam, Israt S and Koladiya, Abhishek and Dai, Sheng Yao and James, Michelle and Rao, Jianghong and Beziere, Nicolas and Daldrup-Link, Heike E},
  title = {B7–H4 ImmunoPET Imaging Tracks Tumor-Associated Macrophage Changes in Prostate Cancer},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.5c00637}
}
Kostenlos starten →